21世纪经济报道记者 唐唯珂 广州报道4月25日,苏州瑞博生物技术股份有限公司(以下简称“瑞博生物”)正式向港交所递交主板上市申请,联席保荐人为中金公司与花旗银行。这是继2021年科创板终止审核后,这家中国小核酸药物企业的又一重大资本动作。公司曾于2020年12月29日申报科创板并获受理,在经过一轮问询与回复后撤回申报材料,2021年5月21日被上交所终止。据招股书披露,瑞博生物成立于2007年,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.